The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the People’s Republic of China (PRC) issued a notice that the patent information registration platform of drugs approved in the PRC will be put into official operation soon.[1] The CDE attached a user manual to specify (1) that the indications provided in each use patent to be registered should be consistent with the indications provided in the package insert of the approved drug; and (2) that each patent to be registered should cover the corresponding technical solution of the approved drug.[2]
[1] The CDE of the NMPA issued the advance notice on ending the testing of the patent information registration platform on June 25, 2021, http://www.cde.org.cn/news.do?method=largeInfo&id=e666ea385204a565.
See https://zldj.cde.org.cn/ for the platform’s official website.
[2] Id.